Kevin M. Downey

Kevin M. Downey defended Elizabeth Holmes from jury selection through deliberations. During voir dire, he questioned prospective jurors about publicity, preexisting opinions, the presumption of innocence and whether a defendant had to present evidence, comprehension, and hardship, and he later participated in disputes over juror service and access to juror-related proceedings.

Downey's cross-examinations tested how witnesses formed and retained their views of Theranos. With commercial partners Steven Burd, Wade Miquelon, and Nimesh Jhaveri, he developed their diligence, contractual safeguards, conditional rollout plans, startup risks, and favorable experiences, while the witnesses maintained that important capabilities or limitations had not been disclosed. His questioning of James Mattis and Daniel Edlin narrowed their technical knowledge and distinguished proposed military evaluations, demonstrations, and external communications from clinical deployment; Edlin nevertheless maintained that his knowledge was limited and described selective reporting and concealed demonstration errors.

With investor witnesses John Bryan Tolbert, Christopher Lucas, and Alan Eisenman, Downey used emails, agreements, prior testimony, risk warnings, and information-rights provisions to challenge recollection, reliance, and the extent of preinvestment diligence. Those witnesses acknowledged varying limits in their contacts, follow-up, or contractual access while continuing to attribute importance to statements from Holmes or Theranos. Downey also sought evidentiary limits, including exclusion of Safeway's renovation-cost figure. The court excluded the exact total while permitting evidence about substantial store changes and rollout preparations.

Downey conducted Holmes's direct and redirect examination across Theranos's origins, technology development, partner relationships, laboratory oversight, military projects, financial projections, regulatory history, and her relationship with Ramesh Balwani. His questions developed her account that scientific, laboratory, and regulatory input informed her beliefs, that trade-secret advice affected disclosure of modified commercial analyzers, and that she lacked fraudulent intent, while her testimony also included acknowledgments concerning pharmaceutical logos, operational problems, and her ultimate authority.

In closing, Downey argued that technology setbacks, investor losses, and laboratory problems did not themselves establish fraudulent intent. He emphasized good faith, development work, risk disclosures, partner diligence, Holmes's asserted reliance on technical and laboratory personnel, and the government's burden to prove guilt beyond a reasonable doubt. When the jury later reported an impasse on three counts, he objected that a modified Allen charge risked coercion; the court overruled the objection and delivered the charge with renewed instructions on the presumption of innocence and reasonable doubt.